Conference Speakers
Cultural Speakers
Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.
At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:
X
Dr. Speakers Full Name
Speaker Credentials
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization and in 2008 sat for and passed the exam administered by the International Board of Lactation Consultant Examiners. As an International Board Certified Lactation Consultant, she now
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization text text text text more name mulder first became interested in breastfeeding in the year 2000, when she became.
X
Abstract: Breastfeeding mothers may turn to formula and/or bottles for many
reasons. Some supplementing with formula by bottle when they reach out for help, and for some moms,
supplementing by alternative methods may be very overwhelming. Some moms need or choose a combination
of breast milk and formula and others may decide to give occasional or regular bottles of expressed
milk. Whatever the reason, as health care professionals helping a mother to breastfeed, it is our
job to be able to help her to reach her own personal goals even when she needs, or chooses to use,
bottles or formula. Learn about baby-led bottle feeding and why it's so important, different types
of formula, their uses and how to prepare them, and how this all fits in with the WHO code and our
code of professional conduct.
View Full Presentation Information & Scheduling
Dr. Speakers Full Name
Speaker Credentials
Speakers (5191)
Dr. Noemi Reguart earned her Medical Degree from the University of Medicine Lleida, in Spain. She completed her postgraduate training and fellowship in the Oncology Department at Hospital Clinic Barcelona. Dr. Reguart gained a PhD focusing on molecular lung cancer biology at the General Thoracic Surgery and Oncology Laboratory, at the University of California San Francisco (UCSF). She has practiced as a Consultant Oncologist at the Department of Medical Oncology in Hospital Clinic Barcelona since 2008. She is a Clinical Professor at the University of Barcelona, deeply committed to under- and postgraduate teaching. Most recently Dr. Reguart has been designated the Director of the Thoracic Oncology Unit at the Hospital Clínic.
Throughout her career, Dr. Reguart has shown her interest in addressing lung cancer. In addition to clinical practice and patient care, she also conducts basic research with a special interest in lung cancer biomarkers and the identification of predictors of therapy response at the August Pi i Sunyer Biomedical Research Institute (IDIBAPS). She has always maintained an active research interest in her own laboratory as well as through several national and international collaborations.
Dr. Reguart is an active member of several international lung cancer organizations including ESMO, IASLC, SLCG, and EORTC, and the author of several scientific publications.
Published in
Speakers
Dr. Paz-Ares (MD, Ph.D.) is currently Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre, Associate Professor at the Universidad Complutense, and Head of the Lung Cancer Unit at National Oncology Research Center, all in Madrid.He graduated with a degree in Medicine from the Universidad Autónoma de Madrid, in 1986, and was trained as a resident in Medical Oncology at Hospital 12 de Octubre (1988-2001). In 1993, he completed a Ph.D. in Medicine at the Universidad Autónoma de Madrid. He was a postdoctoral ESMO Research Fellow in Medical Oncology at the Beatson Oncology Centre, University of Glasgow, (1993– 1995), and completed a Master’s degree in Clinical Pharmacology at the University of Glasgow in 1995.
Before the current position he was Chair of the Medical Oncology Department at the Virgen del Rocío University Hospital in Seville (2007-2014), Head of the Pharmacology Unit and responsible for Early Clinical Studies of Thoracic and Genitourinary Tumours at the University Hospital "12 de Octubre" in Madrid (1995–1999; 2000–2007), and Visiting Research Fellow in the Prostate Cancer Programme at the Dana-Farber Cancer Institute in Boston, MA, USA (1999–2000).Luis Paz-Ares’s research focuses on lung cancer and new therapeutic strategies development, both at the lab and clinical sides, and has published more than 340 articles in peer review journals including New England Journal of Medicine, Lancet, Lancet Oncology, Nature Medicine, Journal of Clinical Oncology and many others. He has served as a member of several committees, including ASCO and ESMO meeting Scientific Committees, European Organisation for Research and Treatment of Cancer Protocol Review Committee and Audit Committee, the Spanish Agency of Medicines and Medical Devices and the European Medicines Agency. He is the Chief Medical Officer of the AECC where he also seats at the Board.
Published in
Speakers
Prof. Giorgio Scagliotti joined the IASLC Board of Directors in 2015, serving as its president-elect and then president from 2015-2019. As Editor, he helped created the IASLC reference book, Thoracic Oncology: The IASLC Multidisciplinary Approach.
Professor of Medical Oncology at Italy’s University of Turin School of Medicine, Dr. Scagliotti is also Chief of Medical Oncology at Turin’s San Luigi Gonzaga Hospital’s Division of Thoracic Oncology. He serves as a member of the administrative board of the University of Torino as well. Prior to his role as Chief of Medical Oncology, Dr. Scagliotti acted as the Head of the Department of Oncology of the University of Torino and served as the Chairperson of the Postgraduate School in Respiratory Medicine.
Professor Scagliotti focuses his research on translational research and targeted molecular therapies for lung cancer. He is principal investigator in European and international clinical trials, including investigator-initiated studies, and is study coordinator for several trials. He has authored or co-authored more than 300 papers in peer-reviewed journals. Professor Scagliotti earned his medical degree and completed his postgraduate training in respiratory medicine, internal medicine and medical oncology at the University of Turin.
Published in
Speakers
Prof. Shun LU, MD, is currently head of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiaotong University.
He served as the leading PI for more than 20 multi-center Phase III oncology clinical trials and participated as the key contributor for more than 50 global and regional clinical trials as well. He has authored more than 200 peer-reviewed articles, many of which has published at JCO, Annuals of Oncology, Clinical Cancer Research, Chest and JTO etc.
Dr. LU currently serves as associate editor for Journal of Thoracic Oncology and Lung Cancer, editor for The Oncologist. Dr. Lu is the advisory board member for Center for Drug Evaluation at NMPA. He is also the chair of Chinese Lung Cancer Association and executive director of CSCO. Dr. LU’s other appointments includes the chair of Oncology Society of Shanghai Medical Association, Chair of Lung Cancer Sub-committee at Oncology Society of Chinese Medical Association, and vice president of the Oncology Branch of Shanghai Medical Doctor Association.
Published in
Speakers
Dr. Yasushi Goto is currently the Assistant chief, Division of Thoracic Oncology, of National Cancer Center (NCC) Hospital, Tokyo. He received his medical degree and doctorate degree in University of Tokyo. He has been working for National Cancer Center Hospital, Tokyo since 2014. His current main researches are medical oncology (thoracic malignancies) and translational medicine. He has engaged in more than 50 scientific papers including Journal of Thoracic Oncology, Journal of Clinical Oncology and Lancet. He is a member of steering committee in several global and domestic studies, and the primary investigators of JCOG trial which is evaluating the efficacy of discontinuing PD-L1 axis inhibitors, and others.
He is also a staff in Section of Knowledge Integration of Center for Cancer Genomics and Advanced Therapeutics and Rare Cancer Center, director of patient supportive organizations, secretary general of JSMO (Japanese Society of Medical Oncology), panel member of guideline and database committee in Japanese Lung Cancer Society, associate editor of Japanese Journal of Clinical Oncology and communication committee member of IASLC (International Association for the Study of Lung Cancer).
Published in
Speakers
Director, Institute of Drug Clinical Trial and Clinical Pharmacology, West China Hospital
Professor, Department of Thoracic Oncology, Cancer Center; and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University
Published in
Speakers
Dr. Hye Ryun Kim is associate professor in the Division of Medical Oncology in Yonsei Cancer Center. She graduated from Yonsei University College of Medicine and trained for Residency and Clinical Fellowship in Internal Medicine and Medical Oncology at Yonsei Cancer Center, Yonsei University College of Medicine. She has focused on the study and development of novel therapeutic agents and modalities in lung cancer and head and neck cancer though clinical trials. Research interests are identification of resistance mechanism to targeted therapy and determinants for tumor-immune microenvironment in lung cancer patients. She leads several clinical trials including investigator-initiated studies focusing on novel approaches for treating these diseases.
Dr. Hye Ryun Kim served as Vice Chief of Lung Cancer Center in Yonsei Cancer Center. She has been a general affair in Lung Cancer Committee and an active member of Korean Cancer Study Group (KCSG). She served as a member of Editorial Board of Yonsei Medical Journal.
Dr. Hye Ryun Kim has been the recipient of several National Research Fund and industry funded grants studying lung cancer and head and neck cancer. Her research interests include immune profiling to identify predictive determinants and hyperprogression for immunotherapy using flow cytometer and genomics and acquired resistant mechanism for targeted therapy in oncogene driven lung cancer patients. She has received funding from the National Research Fund regarding Single-cell multiomics of tumor microenvironment. Dr. Hye Ryun Kim has published more than 100 articles in peer-reviewed journals.
Representative publications
1. Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade JCI Insight. 2020 (Correspondence)
2. Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC Cancer Discov. 2020
3. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer Clin Cancer Res. 2020 (Correspondence)
4. The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression Cancer Res. 2020 (Correspondence)
5. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019 (Correspondence)
6. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. J Immunother Cancer. 2019 (First author)
7. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018 (Co-author)
8. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol. 2017 (Co-first author)
9. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. Ann Oncol. 2017 (First author)
10. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial J Clin Oncol. 2020 (Co-author)
11. Tumor-Infiltrating Regulatory T Cell Accumulation in the Tumor Microenvironment is Mediated by IL33/ST2 Signaling Cancer Immunol Res 2020 (Co-author)
Dr. Hye Ryun Kim served as Vice Chief of Lung Cancer Center in Yonsei Cancer Center. She has been a general affair in Lung Cancer Committee and an active member of Korean Cancer Study Group (KCSG). She served as a member of Editorial Board of Yonsei Medical Journal.
Dr. Hye Ryun Kim has been the recipient of several National Research Fund and industry funded grants studying lung cancer and head and neck cancer. Her research interests include immune profiling to identify predictive determinants and hyperprogression for immunotherapy using flow cytometer and genomics and acquired resistant mechanism for targeted therapy in oncogene driven lung cancer patients. She has received funding from the National Research Fund regarding Single-cell multiomics of tumor microenvironment. Dr. Hye Ryun Kim has published more than 100 articles in peer-reviewed journals.
Representative publications
1. Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade JCI Insight. 2020 (Correspondence)
2. Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC Cancer Discov. 2020
3. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer Clin Cancer Res. 2020 (Correspondence)
4. The Interplay between Slow-Cycling, Chemoresistant Cancer Cells and Fibroblasts Creates a Proinflammatory Niche for Tumor Progression Cancer Res. 2020 (Correspondence)
5. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol. 2019 (Correspondence)
6. Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function. J Immunother Cancer. 2019 (First author)
7. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018 (Co-author)
8. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol. 2017 (Co-first author)
9. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. Ann Oncol. 2017 (First author)
10. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial J Clin Oncol. 2020 (Co-author)
11. Tumor-Infiltrating Regulatory T Cell Accumulation in the Tumor Microenvironment is Mediated by IL33/ST2 Signaling Cancer Immunol Res 2020 (Co-author)
Published in
Speakers
Keunchil Park is Professor of the Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Professor Park had served as Chair of the Lung Cancer Committee of the Korean Cancer Study Group (KCSG) and also served as Chairman of the Board of Directors, Korean Association for Clinical Oncology (KACO).
He has been involved in many IASLC activities since 1996, including Scientific Secretary of the 12th World Conference on Lung Cancer (WCLC; Sept, 2007), and President of the 4th Asia Pacific Lung Cancer Conference (Dec, 2010). He also served the IASLC as the Board of Directors since 2009 to 2013. More recently Prof. Park served as Co-President with Prof. Hisao Asamura of the 18th WCLC, Oct 15-18, 2017, Yokohama, Japan. He received the Merit Award of IASLC in 2016.
Prof. Park is also actively engaged in ASCO as a member of the International Education Steering Group and leads the ASCO Asia Pacific Regional Council as Chair. He also served as Chair of the Korea Actionable Genome Consortium 2015-2018 and the Scientific Co-Chair for ESMO-Asia 2017.
Prof. Park is a member of the ICGC Scientific Steering Committee since 2013 and served as Organizing Chairman of the 13th ICGC workshop, June 12-14, 2017 in Seoul, Korea. He was nominated as Steering Committee member of ICGC-ARGO and recently appointed as Member of the Management Committee.
Published in
Speakers
Dr. Ahn is a board-certified medical oncologist and associate professor at Gachon University Gil Medical Center, Incheon, Korea, with a practice dedicated to the treatment of patients with lung cancer, breast cancer, and head and neck cancers.
Published in
Speakers
Published in
Speakers
